---
title: "AstraZeneca (AZN) was upgraded to a Hold Rating at Deutsche Bank"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299013676.md"
description: "AstraZeneca received a Hold rating and an £117.00 price target from Deutsche Bank analyst Emmanuel Papadakis today. Papadakis covers the Healthcare sector, focusing on stocks such as AstraZeneca, GlaxoSmithKline, and Sanofi. According to TipRanks, Papadakis has an average return of 4.1% and a 52.45% success rate on recommended stocks. In addition to Deutsche Bank , AstraZeneca also received a Hold from HSBC’s Rajesh Kumar in a report issued on September 10. However, yesterday, Berenberg Bank maintained a Buy rating on AstraZeneca (LSE: AZN)."
datetime: "2026-09-15T07:35:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299013676.md)
  - [en](https://longbridge.com/en/news/299013676.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299013676.md)
generator: "portal-rs"
---

# AstraZeneca (AZN) was upgraded to a Hold Rating at Deutsche Bank

AstraZeneca received a Hold rating and an £117.00 price target from Deutsche Bank analyst Emmanuel Papadakis today.

Papadakis covers the Healthcare sector, focusing on stocks such as AstraZeneca, GlaxoSmithKline, and Sanofi. According to TipRanks, Papadakis has an average return of 4.1% and a 52.45% success rate on recommended stocks. 

In addition to Deutsche Bank , AstraZeneca also received a Hold from HSBC’s Rajesh Kumar in a report issued on September 10. However, yesterday, Berenberg Bank maintained a Buy rating on AstraZeneca (LSE: AZN).

### Related Stocks

- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)
- [HSBC.US](https://longbridge.com/en/quote/HSBC.US.md)
- [HSBH.US](https://longbridge.com/en/quote/HSBH.US.md)
- [HSBA.UK](https://longbridge.com/en/quote/HSBA.UK.md)
- [DB.US](https://longbridge.com/en/quote/DB.US.md)
- [DBK.DE](https://longbridge.com/en/quote/DBK.DE.md)
- [GSK.US](https://longbridge.com/en/quote/GSK.US.md)
- [SNY.US](https://longbridge.com/en/quote/SNY.US.md)
- [03KB.DE](https://longbridge.com/en/quote/03KB.DE.md)
- [DPB.DE](https://longbridge.com/en/quote/DPB.DE.md)
- [GSK.UK](https://longbridge.com/en/quote/GSK.UK.md)
- [GSK.WI.US](https://longbridge.com/en/quote/GSK.WI.US.md)
- [SNYNF.US](https://longbridge.com/en/quote/SNYNF.US.md)
- [DTIW.SG](https://longbridge.com/en/quote/DTIW.SG.md)
- [00005.HK](https://longbridge.com/en/quote/00005.HK.md)

## Related News & Research

- [AstraZeneca: Buy Rating Reaffirmed on Robust Pipeline and Attractive Valuation; Price Target Unchanged at $16,500](https://longbridge.com/en/news/298918563.md)
- [AstraZeneca: SERENA-4 Trial Of Etcamah Palbociclib Combination Fails To Meet Primary Objective](https://longbridge.com/en/news/298875452.md)
- [AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears](https://longbridge.com/en/news/298828016.md)
- [AstraZeneca publishes transcript of ERS 2026 investor call and webcast](https://longbridge.com/en/news/298346504.md)
- [AstraZeneca's breast cancer drug fails in late-stage trial](https://longbridge.com/en/news/298768423.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**